HER2 Negative Breast Carcinoma trials recruiting in Ohio

All HER2 Negative Breast Carcinoma trials nationally

Cities in Ohio

Recruiting trials in Ohio

• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Centerville, Cleveland, Columbus, Dayton
• Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
  NCT05677802 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · Ohio: Cleveland, Columbus
• Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
  NCT06026657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Columbus
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
  NCT07391774 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Canton, Columbus